• Home
  • About Us
  • Health Insurance Companies

Health Plan News

Timely Health Plan News and Commmentary.

Health Plan News
Home Medical And Healthcare HearUSA Reports Second Quarter 2010 Results

HearUSA Reports Second Quarter 2010 Results

Posted on August 10, 2010 Written by Annalyn Frame

SOURCE: HearUSA

WEST PALM BEACH, FL–(Marketwire – August 10, 2010) – HearUSA, Inc. (NYSE Amex: EAR), a
leader among the nation’s hearing care providers, reported financial
results for the second quarter ended June 26, 2010.

Financial Results for Second Quarter 2010

In the second quarter of 2010, net revenues increased 9% to $21.4 million
from $19.6 million in the previous quarter, but decreased 6% from $22.7
million in the second quarter of 2009. The decrease year-over-year was
principally the result of some insurance plans eliminating, changing or
limiting their hearing care benefits at the beginning of 2010. The company
implemented a number of plans and strategies during the first quarter of
2010 which helped to replace most of the lost insurance business, including
increased marketing to its existing insurance base and private pay
customers. The company also increased the marketing of its AARP Hearing
Care Program and made it available to AARP members in 45 states through all
177 HearUSA centers and a network of independent AARP Hearing Care Program
providers. These combined efforts were the primary cause of the 9% increase
in second quarter revenue over the previous quarter.

The loss from continuing operations totaled $1.9 million in the second
quarter of 2010, compared to a loss of $2.5 million in the previous
quarter, and income of $963,000 in the second quarter of 2009. The loss
from continuing operations includes AARP advertising costs of $957,000
incurred in the second quarter of 2010 compared to $253,000 in the previous
quarter and none incurred in the second quarter of 2009. Advertising,
royalties and administrative costs associated with the AARP program totaled
$1.3 million in the second quarter of 2010, $588,000 in the previous
quarter and $142,000 in the second quarter of 2009.

Net loss attributable to common stockholders was $2.2 million or $(0.05)
per basic and diluted share in the second quarter of 2010, as compared to a
net loss of $2.7 million or $(0.06) per basic and diluted share in the
previous quarter of 2010, and net income of $1.1 million, or $0.03 per
basic and $0.02 per diluted share, in the same year-ago period. Net loss
attributable to common shareholders in the second quarter of 2009 included
income from discontinued operations of $336,000 or $0.01 per basic and
diluted share.

Management Commentary

“Our focus during the second quarter of 2010 was to increase revenues to
offset the loss of the managed care business in the first quarter and to
expand the reach of the AARP program,” said Stephen Hansbrough, CEO and
chairman of HearUSA. “The 9% increase in revenues over the first quarter of
2010 and the successful launch of the AARP program to AARP members in a
total of 45 states has given us a strong base for continued success going
into the third quarter.

“We have seen appointments grow at an accelerating pace since we launched
our AARP national advertising campaign, and AARP included the HearUSA
program in its publications and web sites in the latter half of the second
quarter. We expect this momentum to continue and believe that center
revenues will grow between 9% and 15% in the second half of 2010 when
compared to the first half, and our target is to grow center revenues 15%
to 20% in 2011 when compared to 2010.

“We will focus primarily on expanding the number of independent providers
participating in the AARP network during the rest of 2010 and expect to
have more than 800 participating providers by the end of the year,”
continued Mr. Hansbrough. “Both HearUSA and AARP will also continue to
increase awareness and member communications during the remainder of the
year. We believe that it will take time to fully develop the provider
network and educate the AARP membership base. Our targets for 2011 are to
expand the AARP network to more than 2,000 participating providers and
generate AARP network sales of over 30,000 units.”

Conference Call

HearUSA will hold a conference call at 4:30 p.m. Eastern time, August 10,
2010, to discuss its second quarter 2010 financial results. The company’s
senior management will host the presentation, which will be followed by a
question and answer period.

To participate in the call, dial the appropriate number 5-10 minutes prior
to the start time, request the HearUSA conference call and provide the
conference ID: 7HEARUSA.

Date: Tuesday, August 10, 2010
Time: 4:30 p.m. Eastern time (1:30 p.m. Pacific time)
Domestic callers: 1-800-862-9098
International callers: 1-785-424-1051
Conference ID#: 7HEARUSA

A Web simulcast and replay will be available via the investor relations
section of the company’s website at www.hearusa.com.

If you have any difficulty connecting with the conference call or webcast,
please contact the Liolios Group at 1-949-574-3860.

A telephone replay of the call will be available later that evening and
will be accessible until August 17, 2010:

Toll-free replay number: 1-877-870-5176
International replay number: 1-858-384-5517
Replay Pin Number: 11721

About HearUSA

HearUSA is the recognized leader in hearing care for the nation’s top
managed care organizations through its 177 company-owned centers and
network of more than 2,000 hearing care providers. HearUSA is the nation’s
only hearing care provider accredited by URAC, an independent, nonprofit
health care accrediting organization dedicated to promoting health care
quality through accreditation, certification and commendation. HearUSA is
also the administrator of the AARP Hearing Care Program, designed to help
millions of Americans aged 50+ who have untreated hearing loss. For more
information about HearUSA visit www.hearusa.com, or go to
www.hearingshop.com for a wide selection of hearing related products
available for purchase online.

Forward Looking Statements

This press release contains forward-looking statements within the meaning
of the Securities Litigation Reform Act of 1995, including those statements
that HearUSA plans to expand its AARP program to include more than 800
participating independent hearing care providers during the course of 2010
and over 2,000 participating providers in 2011; that the company expects
second quarter 2010 momentum to continue; that the company believes that
center revenues will grow between 9% and 15% in the second half of 2010
when compared to the first half of 2010; that the company’s target is to
grow revenues 15% to 20% in 2011 when compared to 2010; and that the
company plans to generate AARP network sales of over 30,000 units. These
statements involve certain risks and uncertainties that could cause actual
results to differ materially from those in the forward-looking statements.
Potential risks and uncertainties include such factors as the company’s
continuing ability to replace lost and decreased revenue from insurance
contracts with increased self-pay revenue, replacement insurance agreements
and other revenue; the company’s ability to attract and retain a sufficient
number of independent providers in all 50 states to participate in the AARP
program; the company’s ability to successfully integrate the AARP program
into its company-owned centers; the ability of the Company to capitalize on
the advertising efforts for the AARP program; the company’s ability to
control costs; the company’s ability to generate sufficient cash flows to
fund its various advertising campaigns; the ability of the company to
maintain unit sales of Siemens hearing aids; market demand for the
company’s goods and services; changes in the pricing environment; general
economic conditions in those geographic regions where the company’s centers
are located; consumer confidence in the general economy; the impact of
competitive products; and other risks and uncertainties described in the
company’s filings with the Securities and Exchange Commission, including
the company’s Form 10-K for the fiscal year ended December 26, 2009.



                               HearUSA, Inc.
                  Consolidated Statements of Operations
            Three Months Ended June 26, 2010 and June 27, 2009
                                (unaudited)


                                                 June 26,       June 27,
                                                   2010           2009
                                               ------------   ------------
                                                 (Dollars in thousands,
                                                except per share amounts)

Net revenues
Hearing aids and other products                $     19,796   $     20,653
Services                                              1,613          2,014
                                               ------------   ------------
Total net revenues                                   21,409         22,667
                                               ------------   ------------

Operating costs and expenses
Hearing aids and other products                       5,290          5,072
Services                                                412            388
                                               ------------   ------------
Total cost of products sold and services
 excluding depreciation and amortization              5,702          5,460

Center operating expenses                            12,209         10,908
General and administrative expenses                   3,769          3,661
Depreciation and amortization                           564            588
                                               ------------   ------------
Total operating costs and expenses                   22,244         20,617
                                               ------------   ------------
Income (loss) from operations                          (835)         2,050
Non-operating income (expenses)
Gain (loss) on foreign exchange                          (5)           375
Interest income                                           5              -
Interest expense                                       (841)        (1,252)
                                               ------------   ------------
Income (loss) from continuing operations
 before income tax expense                           (1,676)         1,173
Income tax expense                                     (220)          (210)
                                               ------------   ------------
Income (loss) from continuing operations             (1,896)           963
Discontinued operations attributable to
 HearUSA, Inc.
Income from discontinued operations, net of
 income tax benefit of $270 in 2009                       -            250
Gain on sale of discontinued operations                   -          1,632
Income tax expense on sale of discontinued
 operations                                               -         (1,546)
                                               ------------   ------------
Income from discontinued operations                       -            336
                                               ------------   ------------
Net income (loss)                                    (1,896)         1,299

Net income attributable to noncontrolling
 interest                                              (238)          (131)
                                               ------------   ------------
Net income (loss) attributable to HearUSA,
 Inc.                                                (2,134)         1,168
Dividends on preferred stock                            (32)           (35)
                                               ------------   ------------

Net Income (loss) attributable to HearUSA,
 Inc. common stockholders                      $     (2,166)  $      1,133
                                               ============   ============

Loss from continuing operations attributable
 to HearUSA, Inc. common stockholders per
 common share - basic                          $      (0.05)  $       0.02
                                               ============   ============
Loss from continuing operations attributable
 to HearUSA, Inc. common stockholders per
 common share - diluted                        $      (0.05)  $       0.02
                                               ============   ============

Net loss attributable to HearUSA, Inc. common
 stockholders per common share - basic         $      (0.05)  $       0.03
                                               ============   ============
Net loss attributable to HearUSA, Inc. common
 stockholders per common share - diluted       $      (0.05)  $       0.02
                                               ============   ============

Weighted average number of shares of common
 stock outstanding - basic                           44,922         44,837
                                               ============   ============

Weighted average number of shares of common
 stock outstanding - diluted                         44,922         45,340
                                               ============   ============

Amounts attributable to HearUSA, Inc. common
 stockholders:

Income (loss) from continuing operations, net
 of tax                                        $     (2,134)  $        832
Discontinued operations, net of tax                       -            336
                                               ============   ============

Net income (loss) attributable to HearUSA,
 Inc. common stockholders                      $     (2,134)  $      1,168
                                               ============   ============





                               HearUSA, Inc.
                        Consolidated Balance Sheets
                                (unaudited)


                                                 June 26,     December 26,
ASSETS                                             2010           2009
                                               ------------   ------------
                                                 (Dollars in thousands,
                                                except per share amounts)
Current assets
Cash and cash equivalents                      $      4,026   $      7,037
Short-term marketable securities                      1,306          4,106
Accounts and notes receivable, less allowance
 for doubtful accounts of $677 and $616               5,506          5,554
Inventories                                           1,409          1,844
Prepaid expenses and other                              417            464
                                               ------------   ------------
Total current assets                                 12,664         19,005
Property and equipment, net                           3,463          4,021
Goodwill                                             51,928         51,495
Intangible assets, net                               12,529         12,816
Deposits and other                                      698            731
Restricted cash and cash equivalents                  3,252          3,245
                                               ------------   ------------
Total Assets                                   $     84,534   $     91,313
                                               ============   ============

LIABILITIES AND STOCKHOLDERS'  EQUITY
Current liabilities
Accounts payable                               $      9,458   $      7,070
Accrued expenses                                      1,907          2,253
Accrued salaries and other compensation               3,224          3,520
Current maturities of long-term debt                  5,357          5,983
Income taxes payable                                      -          1,974
Dividends payable                                        35             35
                                               ------------   ------------
Total current liabilities                            19,981         20,835
                                               ------------   ------------
Long-term debt                                       33,781         36,139
Deferred income taxes                                 7,775          7,335
                                               ------------   ------------
Total long-term liabilities                          41,556         43,474
                                               ------------   ------------
Commitments and contingencies
                                               ------------   ------------

Stockholders' equity
Preferred stock (aggregate liquidation
 preference $2,330, $1 par, 7,500,000 shares
 authorized)
Series H Junior Participating
 (none outstanding)                                       -              -
Series J (233 shares outstanding)                         -              -
                                               ------------   ------------
Total preferred stock                                     -              -

Common stock: $.10 par; 75,000,000 shares
 authorized 45,451,160 and 45,381,750 shares
 issued                                               4,545          4,538
Additional paid-in capital                          138,359        137,863
Accumulated deficit                                (119,804)      (114,982)
Treasury stock, at cost: 523,662 common shares       (2,485)        (2,485)
                                               ------------   ------------
Total HearUSA, Inc. Stockholders' Equity             20,615         24,934

Noncontrolling interest                               2,382          2,070
                                               ------------   ------------
Total Stockholders' equity                           22,997         27,004
                                               ------------   ------------
Total Liabilities and Stockholders' Equity     $     84,534   $     91,313
                                               ============   ============

Company Contact:
HearUSA, Inc.
Stephen J. Hansbrough
Chairman and CEO
Tel 561-478-8770, ext. 132

Investor Relations
Scott Liolios or Ron Both
Liolios Group, Inc.
Email: Email Contact
Tel 949-574-3860

Filed Under: Medical And Healthcare

Recent News

  • Study Reveals Most Kids Hospitalized for Allergic Reactions Could Be Home in Two Hours June 10, 2025
  • Fidelis Care Launches Major Grant Push to Fix Gaps in Postpartum Mental Health Care June 10, 2025
  • DarioHealth Strikes Gold with Major Health Plan Deal, Boosting Revenue and Market Position March 18, 2025
  • Texas Patients Left in the Dark? This Bill Aims to Change That March 17, 2025
  • Health Insurance Denied Your Claim? This Company is Stepping In to Pay for Your Care March 6, 2025
  • Big Changes in Atlanta—Peach State Health Plan Invests in a Major Housing Overhaul March 6, 2025
  • Wellmark Joins Forces with Evio Pharmacy to Make Medications More Affordable March 6, 2025
  • Raintree Systems Snaps Up Yoomi Health in a Bold AI Move for Rehab Therapy January 24, 2025
  • Medicare’s New $2,000 Cap: How Enrollees Will Save Thousands in 2025 January 16, 2025
  • Breaking Barriers: How ‘Ohana Health Plan is Reshaping Care for Hawaii’s Most Vulnerable January 16, 2025

Search Our Site

Categories

  • AARP
  • Blue Cross Blue Shield
  • Canadian Health Care System
  • CIGNA HealthCare
  • COVID-19
  • Facilities And Providers
  • FDA
  • Health Clinics
  • Healthcare Companies
  • Healthcare Plan News
  • Humana
  • MedBasics
  • Medical And Healthcare
  • Medical Malpractice
  • Medicare
  • Senior News
  • The SCOOTER Store

Our Partners

Portal of Dallas
Auto News Review
OSS News Review
Holly Bushes
Rose Bushes
SatelliteDish.Net
I Go Cars
Bad School Photos
Canonical Tag
Check A Domain
Idaho Resorts
iWannaBeFamous
Mabank Online
Stockyards
TravelXL

Pages

  • 1199 National Benefit Fund
  • A Little about Drug Preparation and Formulation Development
  • About Us
  • Achieve Your Weight Goals with Advanced Thermogenic with NMN
  • Affordable Health Insurance
  • Anavar: A Deep Dive into Athletic Benefits, Potential Side Effects, and Weight Loss Applications
    • Anavar Cycle: Benefits, Dosages, and Side Effects
      • Anavar Cycle: Benefits, Dosages, and Side Effects
    • Deca Durabolin vs Anavar: Comparing Performance Enhancers
  • B12 Elite Elixir: Vitalizing Your Health and Energy Levels
  • Benefits of Hiring a Senior Caregiving Service
  • Catastrophic Health Insurance
  • Cheap Health Insurance
  • Cheap Health Insurance Plans
  • Child Health Insurance Plans
  • Choosing a Health Insurance Plan
  • Christian Health Insurance
  • Dental Assistants and Their Future
  • Disclaimer
  • Dr. Howard Bellin: Questions about Rhinoplasty
  • Elite Health Online Dual Stack approach: Unlock your weight loss potential
  • Elite Thermogenic Formula: A Game-Changer in Weight Management and Metabolic Health
  • Finding the Right Dentist
  • Get Your Winks in Blink
  • Harnessing the Power of HGH for Vitality and Youthfulness
  • Health Insurance
  • Health Insurance Plans For Family
  • Health Sharing Plans
  • Healthcare and Hospitals: Disinfection is Key
  • High Deductible Health Plans
  • Home Care Employment in Arizona
  • Hormone Replacement Therapy
    • Harmonizing Body and Spirit: Navigating through Hormone Replacement Therapy
    • Hormone Replacement Therapy (HRT) – A Double-Edged Sword
    • Hormone Replacement Therapy (HRT): A Guide to Rebalancing Hormones
    • Hormone Replacement Therapy (HRT): Balancing the Benefits, Side Effects, and Menopausal Relief
    • Hormone Replacement Therapy: Benefits & Considerations
  • Hot ROCS: The Ultimate Solution for Enhanced Energy and Metabolism
  • How A Medical Weight Loss Plan Can Help You Get The Figure You Want
  • How Ketamine Therapy Helps Fight Depression
  • How Orthotic Insoles Improve Your Health
  • Individual Health Insurance Plans
  • Ketamine Uses and Benefits
  • List of Health Insurance Companies
  • Low Income Health Insurance
  • Medical Device CROs: The Role in Research and Development
  • Medical Malpractice
  • Medical Research Consultants
  • Menopause and HRT
  • Mounjaro (Tirzepatide): A Breakthrough in Diabetes and Obesity Management
  • Nicotinamide Adenine Dinucleotide – Unleashing Vital Molecule Power for Optimal health
    • Unlocking the Power of NMN in Our Advanced Thermogenic and NMN Formula
  • Oxytocin Benefits
    • Oxytocin: The Love Hormone Decoded
    • Oxytocin: The Love Hormone’s Role in Bonding and Beyond
  • Oxytocin Benefits and Hormone Therapy
  • Peptides: The Future of Health and Wellness
    • Semax Peptide – A Glimpse into Nootropic Advancements
  • Personal Lubricants for Women – Liven Up Your Life!
  • Phentermine: Benefits, Usage, and Potential Side Effects
  • Privacy Policy
  • Private Health Insurance Plans
  • Rapamycin, the anti-aging marvel and its multidimensional health benefits
    • Rapamycin: The Anti-Aging Wonder Drug
  • Rhesus Negative
  • Self Employed Health Insurance
  • Semaglutide: A Safe and Effective Alternative to Surgical Weight Loss
    • Semaglutide and its Weight Loss Benefits
    • Semaglutide: A Revolutionary Treatment Explored
    • Semaglutide: Bridging Diabetes Treatment and Weight Loss While Managing Side Effects
    • Semaglutide: Revolutionizing Weight Loss and Diabetes Management
    • Semaglutide: Transforming Weight Management and Glycemic Control
  • Short Term Health Insurance Plans
  • Student Health Insurance Plans
  • Temporary Health Insurance
  • Terms of Use
  • Testosterone Replacement Therapy Insights
    • Exploring the HCG Diet: Unveiling a Unique Pathway Towards Weight Management
    • Testosterone for Females: Balancing Health & Wellness
      • Testosterone for Females: Exploration of Hormonal Balance and Health
    • Testosterone Replacement Therapy (TRT): A Comprehensive Guide
    • Unlocking the Pivotal Role of Testosterone in Holistic Wellbeing
  • Testosterone Therapy: Weighing the Benefits, Risks, and Identifying Symptoms
    • The Vital Role of Testosterone in Health & Well-being
  • The Basic Building Blocks For a Sustained, Healthy Diet
  • The Importance of Clinical Study Software
  • The Marvels and Misgivings of Rapamycin: A Glimpse into Anti-aging and Longevity Benefits
  • The Use of Post Cycle Therapy Supplements
  • Timeless Beauty Med Spa: Elevating Skincare in Dallas, Texas
    • Achieve Your Body Goals with Emsculpt Neo: Now Available at Timeless Beauty Med Spa in Dallas, Texas
    • The Ultimate Guide to Facials: A Path to Radiant Skin
  • Travel Health Insurance
  • Ultimate Guide for Anavar Cycles
  • Understanding Metformin: Benefits and Insights
    • Metformin: A Pillar of Hope in Weight Loss Journeys
    • Metformin: The Multifaceted Medication for Modern Health Challenges
  • Understanding Nandrolone: Benefits and Uses
    • Demystifying Nandrolone: Uses, Potential Benefits, and Considerations
    • Nandrolone for Joint Pain: Efficacy, Benefits, and Considerations
    • Nandrolone: From Muscle Building to Therapeutic Uses and Side Effects
  • Unleash your Potential with Nandrolone & Deca Durabolin
  • Unleashing Glutathione’s Power: The Key to Anti-Aging and Health
  • Unlocking Testosterone’s Power: A Comprehensive Guide to Better Health
  • Winstrol – Beyond the World of Bodybuilding
    • Unlocking the Potential of Winstrol: Dosage, Benefits, and Risks

Copyright © 2025 - Privacy Policy - Terms of Use - Disclaimer